News & Updates
Filter by Specialty:
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
07 May 2025
Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.
Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
05 May 2025
Metformin shows knee OA pain-relieving potential
Metformin, a common medication for diabetes, appears to produce a moderate reduction in knee pain and stiffness for overweight or obese individuals with symptomatic knee osteoarthritis (OA), as shown in the results of a randomized clinical trial.